Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm signs cancer agreement with Kirin Brewery
Under the terms of the agreement, Debiopharm will fully manage and fund the development of Debio-0719, before out-licensing to sales and marketing partners in all territories outside of
Under the terms of the agreement, Debiopharm will fully manage and fund the development of Debio-0719, before out-licensing to sales and marketing partners in all territories outside of
Teva is the first company to file a copycat version of Focalin for approval and, as a result, has been awarded a 180-day period of marketing exclusivity. The
“Although we had data from previous toxicology studies, we decided to undertake additional studies in pigs and monkeys. The studies in monkeys were not required to proceed with
OctoPlus believes that Locteron has the potential to induce fewer side effects, improve patient compliance and provide a more convenient once every two weeks dosing schedule compared with
The compound, XL418 is an inhibitor of protein kinase B (PKB or AKT) and S6 Kinase (S6K), key components of the phosphoinosotide-3 kinase (PI3K) signaling pathway. Activation of
Lexicon's planned name change will be submitted for shareholder approval at its upcoming annual shareholder meeting. The company has the goal of advancing 10 drug candidates into human
In the phase IIa study, the primary endpoint was an expected improvement in AQLQ compared to placebo and the secondary endpoints incorporated measures of asthma control. “The profile
Platinum based therapy is the most widely used chemotherapy to treat ovarian cancer, but some women develop resistance to it. “There are very few drugs that will effectively
The cytomegalovirus (CMV) alphavaccine, which contains three gene targets from CMV, will first be tested in healthy volunteers before being testing in target populations such as solid organ
Vidaza has already been approved by the FDA in 2004, as a drug to be administered subcutaneously, for patients with myelodysplastic syndromes. The FDA approval of intravenous (IV)